- De-Risking a Rare Disease Launch Starts with PrecisionWhy traditional models fall short in rare disease commercialization—and what works instead.Fierce Biotech · 1mo ago↗ source
- <![CDATA[Dr Meeks on a Real-World Study of BCG Retreatment After BCG Failure in NMIBC]]><![CDATA[Joshua J. Meeks, MD, PhD, discusses data from a real-world study of BCG retreatment after BCG failure in NMIBC.]]>onclive · 2mo ago↗ source
- <![CDATA[Dr Hafron on a Multidisciplinary Quality Initiative Designed to Mitigate the AEs of ADT in Prostate Cancer]]><![CDATA[Jason Hafron, MD, discusses findings from a study that evaluated the implementation of a multidisciplinary quality initiative in prostate cancer.]]>onclive · 2mo ago↗ source